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ABSTRACT 
Although historically research has focused on transcription as the central governor of protein 
expression, protein translation is now increasingly being recognized as a major factor for 
determining protein levels within cells. The central nervous system relies on efficient 
updating of the protein landscape. Thus, coordinated regulation of mRNA localization, 
initiation, or termination of translation is essential for proper brain function. In particular, 
dendritic protein synthesis plays a key role in synaptic plasticity underlying learning and 
memory as well as cognitive processes. Increasing evidence suggests that impaired mRNA 
translation is a common feature found in numerous psychiatric disorders. In this review, we 
describe how malfunction of translation contributes to development of psychiatric diseases, 
including schizophrenia, major depression, bipolar disorder, and addiction. 
Introduction 
Precise and dynamic control of the translation of mRNA to proteins is essential for the proper 
function of all cell types. However, because of their extremely polarized morphology, neurons 
rely on the spatial localization of mRNA translation machinery. Since the first identification of 
synapse-associated polyribosome complexes (Steward and Levy 1982), it has been well 
established that in addition to the cell body, mRNAs are stored in dendritic compartments, 
where polyribosomes, translation factors, tRNAs, and tRNA synthetases are also present, 
forming a functional molecular translational machinery (Holt and Schuman 2013). 
Translational machinery is also present in axons and intra-axonal protein synthesis plays 
critical roles in axonal function, development and repair (Kar and others 2018; Sahoo and 
others 2018). However, axonal protein translation will not be discussed herein, as the review 
focuses on local translation in dendrites. Local synthesis of proteins requires the trafficking of 
mRNAs along microtubules, carried by molecular motors, and in order to spatially restrict 
protein synthesis, mRNAs are translationally repressed until they reach their final destination 
(Van Driesche and Martin 2018). 
In 1963, Flexner and colleagues revealed that long-term memory requires protein synthesis 
(Flexner and others 1963). Nowadays, it is well established that synaptic plasticity underlying 
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learning and memory processes requires de novo local protein synthesis, and numerous 
studies have linked active translation of synaptic mRNAs in dendrites with synaptic plasticity 
(Buffington and others 2014). Furthermore, temporal control of mRNA translation is crucial 
for neurons to rapidly respond to environmental changes by modifying the composition of 
synaptic proteins (Holt and Schuman 2013). Local translation is also required for experience-
dependent long-term modifications of synapses, which are hallmark of synaptic plasticity 
(Holt and Schuman 2013). 
As proper functioning of synapses and neural circuits critically relies on tight spatial and 
temporal control of synaptic protein composition, it is not surprising that altered synaptic 
protein synthesis has been increasingly associated with pathophysiology of psychiatric 
disorders. In this review, we first give an overview of the translational machinery. We then 
discuss the implications of dysregulated local dendritic translation on psychiatric disorders, 
including schizophrenia, major depression, bipolar disorder, and addiction. 
Overview of mRNA translation 
INITIATION 
CAP-DEPENDENT INITIATION OF TRANSLATION 
Translation initiation is initiated by a set of reactions mediated by eukaryotic initiation factors 
(eIFs) that lead to the assembly of a functional 80S ribosome, in which the AUG start codon 
of the mRNA is base-paired with the anticodon of the initiator methionyl-tRNA (Met-tRNAi) in 
the ribosomal peptidyl-decoding site (Jackson and others 2010). Figure 1 depicts the 
sequence of events leading to the formation of an active translation initiation complex. 
NON-CANONICAL INITIATION OF TRANSLATION 
The translation initiation of most mRNAs involves a cap-dependent process and ribosomal 
scanning described in Figure 1. However, an increasing number of studies suggest that 
mRNAs are also being translated through non-canonical processes (James and Smyth 
2018), and some short 5′UTR (untranslated region) mRNAs are efficiently being translated 
using a cap-dependent scanning-free process, which involves the translation initiation of 
short 5′UTR (TISU) element (Haimov and others 2015). Other mRNAs undergoing non-
canonical translation bear structural elements called internal ribosomal entry sites (IRES), 
which allow the direct recruitment of the ribosome through a cap-independent mechanism 
(James and Smyth 2018). 
ELONGATION 
During the elongation phase, the ribosomal activity generates a polypeptide chain based on 
the codon sequence of the mRNA. This process requires the translocation of the ribosome 
along the mRNA, the decoding of mRNA codons, and the formation of a peptide bond to 
extend the newly synthesized polypeptide chain (Schuller and Green 2018). Figure 2 depicts 
the details of the elongation phase of translation. 
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Translation termination takes place when a stop codon (UAA, UGA, or UAG) ending the 
coding sequence enters the A-site and involves the cooperation of the two eukaryotic release 
factors eRF1 and eRF3 (Hellen 2018). Figure 3 depicts the detailed events leading to 
translation termination. 
Regulation of mRNA Translation 
The initiation step is considered the rate-limiting step of translation, and as such, this step is 
tightly regulated. However, growing evidence suggests that control of translation elongation 
and termination also play a crucial role in the regulation of mRNA translation. The following 
section provides an overview of the main regulators of mRNA translation. 
INITIATION 
mTORC1 
Mammalian target of rapamycin in complex 1 (mTORC1) is a complex that includes the 
serine/threonine protein kinase, mTOR, the regulatory protein associated with mTOR 
(RAPTOR), the mammalian lethal with Sec13 protein 8 (mLST8), as well as the two 
inhibitory subunits, proline-rich Akt substrate of 40 kDa (PRAS40) and DEP domain 
containing mTOR interacting protein (DEPTOR) (Saxton and Sabatini 2017). mTORC1 
controls cell homeostasis through several anabolic and catabolic processes, integrating 
nutrients and growth factors to activate glycolysis, lipid, nucleotide, and ribosome 
biosynthesis, protein translation, and inhibition of autophagy (Saxton and Sabatini, 2017). 
mTORC1 regulates protein translation through its direct targets 4E-binding protein (4E-BP) 
and ribosomal S6 kinase (S6K) (Fig. 4). In addition to the control of global protein synthesis, 
mTORC1 was thought to preferentially promote the translation of a subset of mRNAs 
containing pyrimidine-rich 5′ terminal oligopyrimidine (TOP) or TOP-like motifs, which are 
typically encoded by genes involved in translation regulation (Nandagopal and Roux 2015; 
Thoreen and others 2012). However, a number of non-TOP mRNAs that are sensitive to 
mTORC1 activity have recently been identified (Gandin and others 2016; Liu and others 
2017), and the identity of the pool of mTORC1-sensitive mRNAs is still uncertain (Meyuhas 
and Kahan 2015; Nandagopal and Roux 2015). mTORC1 plays a key role in local 
dendritic translation by promoting synaptic protein synthesis, and as such the kinase is 
involved in synaptic plasticity, learning, and memory (Lipton and Sahin 2014; Santini and 
others 2014). However, whereas mTORC1 activity is generally associated with increased 
mRNA translation, it can also reduce the local synthesis of specific proteins, particularly in 
diseased states exhibiting excessive mTORC1 activity (Auerbach and others 2011; Niere 
and others 2016; Raab-Graham and others 2006). In addition, as described below, 
accumulating evidence suggest that mTORC1 signaling is dysregulated not only in a 
number of neurological disorders, including neurodevelopmental and neurodegenerative 
diseases, but also in psychiatric disorders, including addiction (Lipton and Sahin 2014; 
Neasta and others 2014). 
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Figure 1. Initiation of translation 
 
Legend. (A) Translation initiation starts with the assembly of the 43S pre-initiation complex (PIC), 
which is formed by the small 40S ribosomal subunit, the elongation initiation factors (eIFs) 1, 1A, 3, 5, 
and eIF2-GTP bound to the initiator Met-tRNAi. (B) At the same time, the eukaryotic initiation factor 4F 
(eIF4F) complex, composed of the RNA helicase eIF4A, the cap-binding protein eIF4E and the 
scaffold protein eIF4G, binds to the cap of the messenger RNA (mRNA), whereas the poly-A binding 
protein (PABP) binds to its poly-A tail, which activates and circularizes the mRNA. (C) The binding of 
the PIC to the 5 ′ end of m
7
-G-capped mRNA is then facilitated by eIF4F complex and eIF3. (D) After 
attachment to the mRNA, the PIC scans the mRNA downstream from 5 ′ to 3 ′, inspecting each codon 
passing through the P-site of the ribosome, until it finds an appropriate AUG start codon. A perfect 
match triggers the arrest of scanning, initiated by the hydrolysis of eIF2-GTP to eIF2-GDP, which 
reduces the affinity of eIF2 for the Met-tRNAi. As a result, eIF2-GDP is displaced from the Met-tRNAi 
by eIF5B-GTP and eIF2-GDP, eIF1A and eIF3 dissociate from the 40S subunit. eIF2-GDP is then 
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cycled by the guanine exchange factor (GEF) eIF2B to eIF2-GTP. (E) The last step of the initiation 
process is the association of the 60S ribosomal subunit to the 48S, catalyzed by eIF5B-GTP, and the 
release of the other eIFs. Finally, the GTP hydrolysis releases eIF5B-GDP to yield the final 80S 
initiation complex, which synthesizes the first peptide bond after accepting the appropriate aminoacyl-
tRNA into the A-site of the ribosome. eIF = eukaryotic initiation factors; GDP = guanosine diphosphate; 
GTP = guanosine triphosphate; PABP = poly-A binding protein; PIC = pre-initiation complex. 
4E-BINDING PROTEIN 
The eIF4E-binding protein family (4E-BP) comprises three members (4E-BP1-3). 4E-BP1 
and 4E-BP2 undergo a hierarchical phosphorylation at Thr37 and Thr46, followed by the 
phosphorylation of four other sites in rodents (five in humans), whereas less is known about 
the regulation of 4E-BP3 (Qin and others 2016). 4E-BPs compete with the eukaryotic 
initiation factor 4G (eIF4G) for a shared binding site on eukaryotic initiation factor 4E (eIF4E) 
(Marcotrigiano and others 1999) (Fig. 4A). The interaction of non-phosphorylated 4E-BPs 
with eIF4E prevents its interaction with eIF4G, inhibiting the assembly of the translation 
initiation complex (Marcotrigiano and others 1999) (Fig. 4A). Upon activation, mTORC1 
phosphorylates 4E-BP, resulting in the release of eIF4E and the recruitment of eIF4G, 
allowing translation to proceed (Lipton and Sahin 2014) (Fig. 4A). Besides mTORC1, several 
other kinases have been described to participate in 4E-BP phosphorylation, these include 
glycogen synthase kinase 3β (GSK3β), extracellular signal-regulated kinase (ERK), 
cyclindependent kinases (CDK), leucine-rich repeat serine/ threonine-protein kinase 2 
(LRRK2), and ataxia-telangiectasia mutated kinase (ATM) (Qin and others 2016). 
p70 RIBOSOMAL S6 KINASE 
p70 Ribosomal S6 kinases (S6K1 and S6K2) are members of the AGC family of 
serine/threonine kinases (Tavares and others 2015). Activation of S6Ks requires the 
phosphorylation of residue Thr229 by phosphoinositide-dependent kinase-1 (PDK1), as well 
as the mTORC1-dependent phosphorylation at Thr389 (Tavares and others 2015) (Fig. 4B). 
S6K phosphorylates several proteins that are associated with mRNA translation, the best 
known being the ribosomal protein S6 (S6), a component of the 40S ribosomal subunit (Fig. 
4B). Phosphorylation of S6 by S6K occurs on five C-terminal residues in a sequential fashion 
(Biever and others 2015b). Phosphorylation of S6 is commonly used as a marker of 
translation activation; however, its biological significance remains controversial (Biever and 
others 2015b). 
Figure 2. Translation elongation 
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Legend. The elongation phase extends from the loading of the first aminoacyl-tRNA into the A-site 
until the ribosome reaches the termination codon. Elongation comprises three major steps: tRNA 
selection (A, B), peptide bond formation (C), and translocation (D, E). (A, B) the aminoacyl-tRNA 
bearing the appropriate anticodon is delivered to the ribosomal A-site by the GTPase eEF1A in a 
ternary complex with the GTP. On matching between codon and anticodon, eEF1A hydrolyses GTP to 
allow aminoacyl-tRNA loading. (C-E) Peptide bond is catalyzed and the growing peptide chain is 
transferred to the tRNA in the A-site. As the peptide bond forms, the ribosomal subunits rotate and 
trigger movement of the tRNAs into so-called hybrid P/E and A/P states, with the acceptor ends of the 
tRNAs in the E and P sites and the anticodon loop remaining in the P and A sites. Translocation of the 
tRNAs to the canonical E and P sites requires the GTPase activity of the elongation factor eEF2 in 
complex with GTP. A = acceptor site; aa-tRNA = aminoacyl-tRNA; E = exit site; eEF = eukaryotic 
elongation factor; P = peptidyl site. 
Besides S6, other substrates of S6K participating in the translation process have been 
described (Tavares and others 2015) (Fig. 4B). For example, S6K-dependent 
phosphorylation of eukaryotic initiation factor 4B (eIF4B) enhances its interaction with 
eukaryotic initiation factor 3 (eIF3) and the recruitment of eukaryotic initiation factor 4A 
(eIF4A) at the translation initiation complex (Shahbazian and others 2006) (Fig. 4B). S6K1-
mediated phosphorylation of the eIF4A inhibitor programmed cell death protein 4 (PDCD4) 
promotes its degradation and further enhances eIF4A activity (Dennis and others 2012). 
Finally, eukaryotic elongation factor 2 kinase (eEF2K), a negative regulator of protein 
synthesis, is phosphorylated by S6K1 (Tavares and others 2015) (Fig. 4B). S6K inhibition is 
mediated by the two phosphatases, protein phosphatase 2A (PP2A) and PH domain and 
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leucine-rich repeat protein phosphatase (PHLPP) (Liu and others, 2011; Peterson and others 
1999). 
Figure 3. Translation termination and recycling 
 
Legend. (A, B) Termination takes place when the ribosome reaches the stop codon (UAA, UGA, or 
UAG) at the end of the coding sequence. Termination in eukaryotes is catalyzed by two collaborating 
factors, eRF1 and eRF3. eRF1 is responsible for the recognition of the stop codon and peptidyl-tRNA 
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hydrolysis, whereas eRF3 is a GTPase. (C, D) Once the polypeptide chain has been released, the 
ribosomal subunits must be dissociated and the mRNA and deacylated tRNA released recycled. The 
multifunctional ABC-family ATPase protein ABCE1 joins the post-termination complex and promotes 
ribosome subunits dissociation and recycling. ABCE1 = ATP-binding cassette sub-family E member 1; 
eRF = eukaryotic releasing factor. 
Figure 4. 4E-BP and S6K regulation in translation initiation control 
 
Legend. (A) The interaction of non-phosphorylated 4E-BP with eIF4E prevents its interaction with 
eIF4G and inhibits the assembly of the translation initiation complex. On activation, mTORC1 
phosphorylates 4E-BP, resulting in the release of eIF4E and the recruitment of eIF4G, allowing cap-
dependent translation to proceed. (B) Activation of S6K requires the PDK1-dependent phosphorylation 
of residue Thr229, as well as the mTORC1-dependent phosphorylation at Thr389. S6K 
phosphorylates the ribosomal protein S6, which is commonly thought to activate translation process. 
S6K-dependent phosphorylation of eIF4B enhances its interaction with eIF3 and the recruitment of 
eIF4A to the translation initiation complex. S6K also phosphorylates the eIF4A inhibitor PDCD4 and 
promotes its degradation while enhancing eIF4A function. Inhibition of S6K is an active process 
mediated by phosphatases, and both PP2A and PHLPP have been shown to dephosphorylate S6K. 
4E-BP = 4E-binding protein; eIF = eukaryotic initiation factor; mTORC1 = mammalian target of 
rapamycin in complex 1; P = phosphorylated residue; PDCD4, programmed cell death protein 4; 
PDK1, protein 3-phosphoinositide-dependent protein kinase-1; PHLPP, PH domain and leucine-rich 
repeat protein phosphatase; PP2A, protein phosphatase 2A. 
Figure 5. eIF2α regulation in translation initiation control.  
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Legend. eIF2 is an heterotrimer composed of α, β, and γ subunits, which binds to GTP and Met-
tRNAi to form the PIC pre-initiation complex. After AUG codon recognition, GTP is hydrolyzed and 
eIF2-GDP is displaced from the Met-tRNAi (see Fig. 1). The recycling of inactive eIF2-GDP to active 
eIF2-GTP requires the guanine nucleotide exchange factor (GEF) activity of eIF2B. Phosphorylation of 
eIF2 on its α subunit (Ser51) by the kinases HRK, PKR, GCN2, or PERK converts eIF2 into a 
competitive inhibitor of eIF2B, which impairs the GDP/GTP exchange and results in a decrease in 
global translation. Inactivation of eIF2α involves dephosphorylation by protein phosphatase 1 (PP1) 
coupled to the protein phosphatase 1 regulatory subunit 15 (PPP1R15). eIF = eukaryotic initiation 
factor; GCN2 = general control non-derepressible-2; HRK = heme-regulated kinase; PERK = PKR-like 
endoplasmic reticulum resident protein kinase; PKR = double-stranded RNA activated protein kinase; 
PP1 = protein phosphatase 1; PPP1R15 = protein phosphatase 1 regulatory subunit 15. 
EUKARYOTIC INITIATION FACTOR 2α 
The eukaryotic initiation factor 2 α (eIF2α) is another key player in the control of translation 
initiation (Jackson and others 2010). Following the scanning of mRNA by the 43S pre-
initiation complex (PIC), eIF2-GTP is hydrolyzed and eIF2-GDP is released (Fig. 1). The 
recycling of inactive eIF2-GDP to active eIF2-GTP requires the guanine nucleotide exchange 
factor (GEF) activity of eIF2B (Fig. 5) (Jackson and others 2010). Phosphorylation of eIF2α 
converts eIF2 into a competitive inhibitor of eIF2B, which impairs the GDP/GTP exchange 
resulting in a decrease in global translation (Fig. 5) (Moon and others 2018). Activation of 
kinases phosphorylating eIF2α not only suppresses general translation but also stimulates 
the translation of specific mRNAs, mostly coding for proteins participating in endoplasmic 
reticulum (ER) stress responses (Fig. 5) (Bellato and Hajj 2016). However, the translational 
shift driven by eIF2α phosphorylation is also part of normal neuronal function in the absence 
of stress, and growing evidence shows that eIF2α is an important regulator of synaptic 
protein translation and synaptic plasticity (Bellato and Hajj 2016; Moon and others 2018).  
 
microRNAS 
microRNAs (miRNAs) are 20 to 22 nucleotides endogenous non-coding RNAs that control a 
broad array of biological processes (Eulalio and others 2008). The genesis of miRNAs 
occurs in the nucleus where the primary miRNA transcript is cleaved by the exonuclease III 
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Drosha to create a precursor miRNA product. The pre-miRNA is then exported to the 
cytoplasm where the RNase Dicer carries out a second processing step by excising the 
terminal loop, to create a mature miRNA duplex. One of the miRNA strands associates with 
Argonaute (AGO) and other proteins to form the RNA-Induced Silencing Complex (RISC) 
(Eulalio and others 2008). Most of miRNAs binding sites lie in the 3′UTR and are usually 
present in multiple copies. miRNA-RISC mediates two modes of gene silencing: mRNA 
decay and translational repression (Iwakawa and Tomari 2015). The general view is that the 
degree of complementarity between miRNA and mRNA is a key determinant of the 
regulatory mechanism: a perfect complementarity leads to the cleavage and degradation of 
the mRNA, whereas the presence of mismatches excludes cleavage and promotes 
repression of translation (Iwakawa and Tomari 2015). Several miRNAs have been identified 
in dendrites and were shown to play a role in local mRNA translation and synaptic plasticity 
(Weiss and others 2015); however, the regulation of miRNA expression at dendrites remains 
poorly understood. Recent evidence suggested that pre-miRNAs are transported and stored 
in dendrites, serving as a local source of miRNAs that can be processed locally into mature 
miRNA (Weiss and others 2015). This conclusion is reinforced by the demonstration that 
Dicer is localized at synapses and its catalytic activity is induced upon neuronal stimulation 
(Weiss and others 2015). 
Figure 6. Translation elongation control 
 
Legend. (A) eEF1A-GTP delivers the aminoacyl-tRNA to the A site of the ribosome (see Fig. 2), and 
following GTP hydrolysis, eEF1A-GDP is released. The recycling of eEF1A-GDP to eEF1A-GTP is 
catalyzed by eEF1B, which is a heteromer composed of at least four subunits: the structural eEF1γ, 
two exchange factors eEF1Bβ and eEF1Bδ, and a unique tRNA synthetase (Val-Rs). (B) eEF2K 
phosphorylates eEF2 at Thr56, inhibiting the binding of eEF2 to the ribosome and resulting in a 
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decrease in global translation. S6K and p90RSK phosphorylate eEF2K on the inhibitory residue 
Ser366, whereas PKA and AMPK activate eEF2K by phosphorylating Ser500 and Ser398, 
respectively. Dephosphorylation of eEF2 is mediated by phosphatases, including PP2A. A = acceptor 
site; AMPK = AMP-activated protein kinase; E = exit site; eEF = eukaryotic elongation factors; eEF2K 
= eukaryotic elongation factor kinase; GDP = guanine diphosphate; GTP = guanine triphosphate; P = 
peptidyl site; p90RSK = p90 ribosomal S6 kinase; PKA = protein kinase A; PP2A = protein 
phosphatase 2A; S6K = S6 kinase; Val-Rs = valine tRNA synthetase. 
ELONGATION 
EUKARYOTIC ELONGATION FACTORS 
Eukaryotic elongation factor 1A (eEF1A) in its GTP-bound form delivers the aminoacyl-tRNA 
to the A site of the ribosome (Dever and Green 2012) (Fig. 2). Following GTP hydrolysis, 
eEF1A-GDP is released and is recycled to eEF1A-GTP by the GEF activity of the eukaryotic 
elongation factor 1B (eEF1B) (Fig. 6A). eEF1A and eEF1B are phosphorylated by a number 
of serine and threonine kinases (Migliaccio and others 2016). For example, protein kinase C 
(PKC) phosphorylates both eEF1A and eEF1B, causing an increase in the GDP/GTP 
exchange activity (Dever and Green 2012). S6 kinases, Rho-kinase, protein kinase A (PKA), 
casein kinase II, and CDKs have also been implicated in the phosphorylation-dependent 
regulation of eEF1A and eEF1B (Migliaccio and others 2016). 
EUKARYOTIC ELONGATION FACTOR 2 KINASE 
Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical calcium calmodulin protein 
kinase (CaMK) (Proud 2015). eEF2K phosphorylates eEF2 at Thr56, thereby inhibiting the 
binding of eEF2 to the ribosome, resulting in a decrease in the elongation rate (Fig. 6B) 
(Proud 2015). S6K regulate eEF2K activity by phosphorylating the inhibitory site Ser366, 
which desensitizes eEF2K to its activation by calmodulin (Fig. 6B) (Wang and others 2001). 
p90 ribosomal S6 kinases (p90RSKs) also phosphorylate eEF2K at Ser366 (Fig. 6B) (Wang 
and others 2001). In addition, two other main pathways are known to activate eEF2K by 
phosphorylation: cAMP-dependent kinase PKA phosphorylates eEF2K at Ser500, which 
makes eEF2K activation less dependent on calcium (Diggle and others 2001), whereas the 
AMP-activated protein kinase (AMPK) stimulates eEF2K activity by phosphorylating Ser398 
in order to slow down translation elongation when cells are in a low-energy status (Fig. 6B) 
(Browne and others 2004). 
RIBOSOME TRANSLOCATION RATE, TRNA, AND CODON OPTIMALITY 
An emerging idea is that modulation of ribosome translocation might be a crucial component 
in the regulation of translational elongation, as ribosome translocation rates may subtly 
influence protein expression (Hanson and Coller 2018; Yu and others 2015). In this view, 
tRNAs can be considered as critical regulators of the transcriptome as not all codons are 
decoded at the same rate (Yu and others 2015). In addition, codon optimality, which defines 
the differential recognition of codons by the translational machinery and reflects the balance 
between the availability of tRNA molecules and their demand during translation process, has 
been shown to be a powerful determinant of mRNA translation elongation (Hanson and 
Coller 2018). 
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The nonsense-mediated mRNA decay (NMD) is a conserved pathway of mRNA degradation 
that recognizes and rapidly degrades select mRNAs (Raimondeau and others 2018). NMD 
was originally identified as a pathway that degrades mRNAs with a premature stop codon 
resulting from transcription errors, pausing, splicing, or damages (Raimondeau and others 
2018). It is now recognized that the NMD also regulates the expression of specific genes by 
degrading mRNAs, and about 5% to 10% of the transcriptome appears to be sensitive to 
NMD (Raimondeau and others 2018). The three core NMD factors are the up-frameshift 
proteins UPF1-3, with UPF1 having RNA helicase activity and UPF2 and UPF3 being 
regulatory factors. Together with other factors, NMD recognizes and elicits the rapid 
degradation of abnormal mRNAs and a subset of normal mRNAs, affecting several 
physiological processes, including stress, immune responses, neurodevelopment, and 
neuronal functions (Raimondeau and others 2018). 
RNA-BINDING PROTEINS 
mRNA processing, transport, stability, degradation, and post-translation regulation are all 
processes carried out by a plethora of RNA-binding proteins (RBPs) (Brinegar and Cooper 
2016). RBPs are essential effectors and regulators of mRNA alternative splicing and 
polyadenylation, which not only generate transcript diversity but also directly influence the 
stability, transport, localization, and translation efficiency of mRNAs (Brinegar and Cooper 
2016). It is becoming increasingly clear that dysregulation of RBPs leads to abnormalities in 
RNA processing, which represent a common feature among many neurological disorders 
(Brinegar and Cooper 2016). 
mRNA localization is highly dependent on RBPs. Specifically, mRNAs are transported along 
microtubules from the soma to dendritic and axonal synapses in ribonucleoprotein 
complexes (RNPs) that are formed by mRNAs and RBPs (Ravanidis and others 2018). RBPs 
within the RNP function as translational repressors to refrain the mRNA from being translated 
before reaching its final destination (Ravanidis and others 2018). The most well-
characterized RBP involved in mRNA translation repression during mRNA transport is the 
Fragile X-linked mental retardation protein (FMRP), whose lack of expression causes the 
Fragile X syndrome (FXS), the most common form of inherited intellectual disability in boys 
(Chen and Joseph 2015). In addition, FMRP also regulates translation by interacting with 
eIF4E, cytoplasmic FMRP-interacting protein 1 (CYFIP1), and miRNAs, trapping target 
mRNAs in cytoplasmic granules, or by slowing or stalling ribosomes (Chen and Joseph 
2015). Other RBPs involved in mRNA repression during transport, mRNA processing and 
stability, are the zip-code-binding protein 1 (ZBP1), Hu/ELAV-like, pumilio (PUM) and staufen 
(STAU) proteins (Brinegar and Cooper 2016; Goldstrohm and others 2018; Perrone-
Bizzozero and Bird, 2013). 
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Dysregulation of mRNA Translation in Psychiatric 
Disorders 
Changes in spine number, morphology, and strength of synaptic connections, collectively 
termed as synaptic plasticity, mainly depend on rapid modification of the synaptic proteome, 
which is regulated by local dendritic translation of mRNAs (Forrest and others 2018). 
Aberrant dendritic spine morphology and function are associated with psychiatric disorders, 
including schizophrenia, depression, bipolar disorder, and addiction (Forrest and others 
2018). Here we focus on the alterations of the regulatory mechanisms of mRNA translation 
associated with major psychiatric disorders (Fig. 7). 
SCHIZOPHRENIA 
Schizophrenia (SZ) is a severe disabling disorder characterized by disturbances in multiple 
brain functions, including cognitive and emotional processes that affects 1% of the population 
(Sarkar and others 2017). Intriguingly, although a strong genetic component exists in the 
etiology of SZ, no specific gene has been shown to be crucial for the development of the 
disorder, and accumulating evidence supports the involvement of synaptic proteins in the 
pathogenesis of the disease (Sarkar and others 2017). Below we describe examples of how 
disruption in mRNA translation contributes to the etiology of SZ. 
mTORC1 AND DISRUPTED IN SCHIZOPHRENIA 1 (DISC1) 
DISC1 is a scaffolding protein that plays a role in dendritic mRNA targeting (Yerabham and 
others 2013). DISC1 knock-down in the hippocampal dentate gyrus (DG) of mice leads to 
deficits in cognitive performances and SZ-like behaviors (Zhou and others 2013). 
Interestingly, treatment of mice with the mTORC1 inhibitor, rapamycin, prevented the 
morphogenesis, excitability, and behavioral deficits resulting from DISC1 knockdown, 
suggesting that mTORC1 is a key contributor to the structural and behavioral deficits 
produced by DISC1 deficiency (Zhou and others 2013). In addition, mTORC1 has also been 
linked to SZ via the serotonin receptor 5-HT6. Specifically, Meffre and colleagues showed 
that rapamycin prevented deficits in social cognition and novel object discrimination induced 
by 5-HT6 agonists, suggesting that recruitment of mTORC1 by 5-HT6 receptors in the 
prefrontal cortex (PFC) contributes to the perturbed cognition in SZ (Meffre and others 2012). 
Meffre and coworkers also showed that 5-HT6 receptors physically interact with mTORC1 
and increase mTORC1 signaling in the rodent PFC (Meffre and others 2012). 
 
TRANSLATION INITIATION AND ELONGATION FACTORS 
Whether translation initiation and elongation factors play a role in SZ has not been explored 
in great detail. However, English and colleagues used a proteomic profiling approach to 
identify protein synthesis pathways disrupted in SZ patient–derived olfactory neurospheres, 
and showed that several ribosomal proteins and eIF2α signaling-related proteins were 
robustly decreased in the SZ group compared with controls (English and others 2015). In 
addition, the authors conducted genome-wide association studies and found that 
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dysregulated eIF2α and eIF4 signaling pathways are correlated with the status of the disease 
(English and others 2015). Furthermore, Topol and colleagues revealed that the expression 
of translation factors and ribosomal proteins including eIF2B, eIF3, eIF4, eEF1 and eEF2, 
were increased in SZ patient– derived induced pluripotent stem cells (iPSC) (Topol and 
others, 2015). Together, these studies suggest of a global dysfunction of the translation 
machinery in SZ patient–derived cells. 
miRNAs 
There is a growing body of literature showing that miRNAs play major roles in the 
pathophysiology of SZ (Gibbons and others 2018). Studies using postmortem SZ samples 
identified numerous miRNAs differentially expressed in the PFC (Gibbons and others 2018). 
Interestingly, many miRNAs whose expression is dysregulated in SZ are known to target 
synaptic proteins. In addition to alterations in miRNA expression, aberrations in miRNA 
biogenesis and processing have also been linked to SZ (Gibbons and others 2018). 
RNA-BINDING PROTEINS 
Dysregulation of several RBPs has been associated with SZ pathogenesis. In particular, the 
level of FMRP and its downstream targets are reduced in the superior frontal cortex of SZ 
patients (Fatemi and others 2017). In addition, large-scale genomic studies in SZ patients 
identified enrichment of uncommon mutations for predicted targets of FMRP (Leonenko and 
others 2017), and a single point mutation (SNP) in matrix metalloproteinase 9 (MMP-9), 
whose 3′UTR is targeted by FMRP, has been associated with SZ (Lepeta and others 2017). 
Moreover, topoisomerase 3β (TOP3β), which encodes for a component of FMRP-containing 
cytosolic messenger RNPs, has also been associated with SZ risk and cognitive impairment, 
highlighting the possible involvement of dysregulated FMRP-related signaling in the 
development of SZ (Stoll and others 2013). Another RBP possibly involved in SZ 
pathogenesis, is ELAV-4/ HuD, which has been shown to interact with the SZ-associated 
allelic variant of Dihydropyrimidinase like 2 (DPYSL2), characterized by a polymorphic 
dinucleotide repeat (DNR) at the 5′UTR (Pham and others 2016). Interestingly, introduction 
of the DPYSL2 DNR allele by CRISPR/Cas9 genome editing in human embryonic kidney 
(HEK) 293 cells resulted in a transcriptome signature that was highly overlapping with the 
results obtained by Chen and colleagues after knockdown of Zinc finger protein 804A 
(ZNF804A) in neural progenitor cells (Chen and others 2015). ZNF804A was highlighted as a 
top candidate gene for SZ in genome-wide association studies (Harrison 2017; O’Donovan 
and others 2008). The precise role of ZNF804A in neuronal function is not fully understood, 
but recent evidence suggest that the protein interacts with many RBPs and other proteins 
involved in mRNA translation, suggesting a role in translation (Harrison 2017). Finally, whole 
exome sequencing studies revealed that a nonsense mutation in RNA-binding-motif protein 
12 (RBM12) is associated with psychosis and SZ (Steinberg and others 2017). This mutation 
results in the production of a truncated protein lacking one of the three predicted RNA-
recognition motifs, which is likely to result in at least partial loss of function (Steinberg and 
others 2017), but further studies on the biological function of RBM12 are needed in order to 
understand the role of this protein in the pathogenesis of SZ. 
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MAJOR DEPRESSIVE DISORDER 
Major depressive disorder (MDD) is a severe and highly debilitating psychiatric disease that 
affects nearly one-fifth of the U.S. population and is the leading cause of disability worldwide 
(Zuckerman and others 2018). In addition to depression, MDD is characterized by 
anhedonia, impairments in cognition, emotional state, memory, and motivation. The disorder 
is also often associated with low self-esteem, low energy, deficits in appetence and suicidal 
behaviors (Zuckerman and others 2018). 
mTORC1 
Several lines of evidence suggest that activation of mTORC1 signaling is beneficial for the 
treatment of MDD (Raab-Graham and others 2016). Specifically, Li and coworkers 
demonstrated that the antidepressant, ketamine, activates mTORC1 in the PFC of rodents, 
increasing synaptic protein synthesis (Li and others 2010). The authors further showed that 
inhibition of mTORC1 activity in the PFC blocked the antidepressant effects of ketamine (Li 
and others 2010). Other studies confirmed that the antidepressant-like effect of N-methyl-d-
aspartate receptors (NMDAR) antagonists requires mTORC1 and synaptic protein synthesis 
in PFC and hippocampal neurons (Workman and others 2013, 2018). These data raise an 
interesting hypothesis that reduction in mTORC1 activity contributes to the etiology of major 
depression. In line with this possibility, cyclosporine A-dependent inhibition of the calcium 
and calmodulin-dependent protein phosphatase, calcineurin, produced depressive-like 
behaviors by blocking the mTORC1 pathway in the rat PFC (Yu and others 2013), whereas 
the muscarinic receptor antagonist, scopolamine, increased mTORC1 signaling and 
synaptogenesis, producing rapid antidepressant behavioral responses (Voleti and others 
2013). Moreover, the antidepressant effects of the selective serotonin reuptake inhibitor 
(SSRI), paroxetine, and the antipsychotic drug, levo-stepholidine, have also been linked to 
mTORC1 signaling (Xu and others 2018; Zhang and others 2017). Finally, Dwyer and 
colleagues demonstrated that increased expression of S6K in the PFC of rats produced 
antidepressant effects, whereas its inhibition resulted in depressive behaviors (Dwyer and 
others 2015). All those data converge to consolidate the hypothesis that malfunction in 
mTORC1 signaling in the PFC, and consequent impairment of protein synthesis contribute to 
the pathology of MDD. 
TRANSLATION INITIATION AND ELONGATION FACTORS 
Interestingly, ketamine-mediated blockade of NMDAR inhibits eEF2K, resulting in the 
reduction of eEF2 phosphorylation and the rapid synthesis of brain-derived neurotrophic 
factor (BDNF) in the hippocampus of mice, suggesting that inhibition of eEF2K contributes to 
the fast-acting behavioral antidepressant-like effects of ketamine (Adaikkan and others 2018; 
Monteggia and others 2013). In addition, the alkaloid berberine produces antidepressant 
effects in ovariectomized mice by modulating the eEF2-BDNF pathway in the hippocampus 
(Fan and others 2017), suggesting an important contribution of eEF2 signaling pathway to 
MDD. In contrast, Dagestad and colleagues showed that the SSRI fluoxetine increased the 
phosphorylation of eEF2 in the PFC, hippocampus and DG of rats (Dagestad and others 
2006), suggesting that different antidepressants may differentially modulate eEF2 function. 
Besides eEF2, other translation initiation factors may also play a role in the development 
and/or maintenance of MDD. For example, two recent studies reported that eIF4E 
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phosphorylation modulates depression-like behaviors through selective mRNA translation 
and regulation of the inflammatory response (Aguilar-Valles and others 2018; Amorim and 
others, 2018). Specifically, the authors showed that ablation of eIF4E phosphorylation at 
Ser209 dysregulates the translation of a subset of mRNAs, exaggerating inflammatory 
responses and reducing serotonin levels, thereby producing depressive-like phenotypes 
(Aguilar-Valles and others 2018; Amorim and others, 2018). In addition, eIF4E 
phosphorylation was shown to mediate the antidepressant action of fluoxetine, providing a 
novel translational control mechanism underlying the pathogenesis of MDD (Amorim and 
others 2018). 
miRNAs 
Several studies have linked MDD with dysregulation of miRNAs (Dwivedi 2016). For 
instance, SNPs in the miRNA machinery have been associated with MDD, including SNPs 
within pre-miR-30e, AGO1, and DGCR8, the latter being part of the microprocessor complex 
and a component of miRNA biogenesis (He and others 2012; Xu and others 2010). 
Interestingly, a postmortem study revealed a significant down-regulation of 21 miRNAs in the 
dorsolateral PFC of depressed suicidal subjects (Smalheiser and others 2012). Smalheiser 
et al. also reported that the expression of several miRNAs is altered in the PFC of rats that 
exhibited learned helplessness, a behavioral paradigm that models depression (Smalheiser 
and others 2011). Furthermore, increased levels of miR-132 and miR-182 (both targeting 
BDNF) and decreased BDNF levels have been reported in the serum of depressive patients 
(Li and others 2013). Finally, miR-132 was suggested as an indicator for depression status 
and for monitoring the effectiveness of treatment (Fang and others 2018). 
RNA-BINDING PROTEINS 
Impaired function of RNA-binding proteins has also been associated with MDD. Specifically, 
recent genetic and brain-imaging studies suggested that bicaudal C homolog 1 (BICC1) may 
be associated with depression (Bermingham and others 2012). BICC1 encodes for an RNA-
binding protein that plays a role in cytoskeletal organization, cell communication and 
regulation of Wnt signaling, a pathway involved in the physiopathology of depression (Voleti 
and others 2012). In addition, Ota et al. showed that BICC1 is up-regulated in the PFC and 
DG of MDD patients, as well as in the PFC and hippocampus of depressed rats (Ota and 
others 2015). The authors also reported that ketamine administration decreases BICC1 
mRNA levels in the hippocampus and that hippocampal BICC1 knock-down attenuated rat 
depression-like phenotypes, identifying a role for BICC1 in the development of depressive 
behaviors (Ota and others 2015). Finally, a role for the ELAV-like RBPs, HuB and HuC, has 
been suggested in the modulation of emotional states, by using a rat model of depression 
induced by unpredictable chronic mild stress (Sanna and others 2018). 
BIPOLAR DISORDER 
Bipolar disorder (BD) is a mood disorder that affects around 2.4% of the global population, 
represents the sixth leading cause of disability worldwide and is characterized by chronic 
depressive and manic episodes (Harrison and others 2018). 
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Several human studies suggested an involvement for the mTORC1 signaling pathway in BD 
pathophysiology. Specifically, decreased mTOR mRNA levels were detected in blood 
samples of short-term BD patients (Machado-Vieira and others 2015), and an SNP in raptor 
has been associated with BD in genetic studies (Rajkumar and others 2015). 
Rodent studies revealed that mania is associated with increased activity of mTORC1. 
Specifically, ouabain, a specific NA/K-ATPase inhibitor, induces hyperactivity in a model of 
mania and increases mTORC1 activity and protein synthesis in prefrontal, cingulate, and 
orbitofrontal cortices (Kim and others 2013). In line with the latter finding, Flaisher-Grinberg 
and colleagues presented data to suggest that rapamycin possesses mood stabilizing 
properties and ameliorates manic-like behaviors in rodent models (Kara and others 2018), 
indicating that BD may be associated with excessive mTORC1 signaling in cortical brain 
regions. On another hand, Lee et al. analyzed the striatal transcriptome of Shank3-
overexpressing transgenic mice, which exhibit manic-like behaviors, and observed a 
significant reduction in mTORC1 activity in the striatum, suggesting that an interaction 
between Shank3 and upstream regulators of mTORC1 might contribute to the induction of 
manic behaviors (Lee and others 2017). Altogether these studies suggest that mTORC1 
signaling may be differentially dysregulated in cortical and striatal areas, but that both 
activation and inhibition of mTORC1 converge toward the development of mania-like 
behaviors. 
TRANSLATION INITIATION AND ELONGATION FACTORS 
Lithium chloride is universally accepted as the first-choice mood-stabilizer for maintenance 
treatment of BD. However, despite the extensive study of its molecular targets, how lithium 
alleviates BD pathologies is not fully understood. Using a proteomic approach, Karyo et al. 
identified eEF2 as a cellular target of lithium (Karyo and others 2010). Specifically, the 
authors show that eEF2 phosphorylation at Thr56 site, a key inhibitory site for eEF2 activity 
is reduced in cultured cells and mouse hippocampus, thus enhancing protein synthesis 
(Karyo and others 2010). This observation suggests that dysregulated protein synthesis may 
partly underlie the pathogenesis of BD. In addition, Pfaffenseller et al. observed an increased 
phosphorylation of eIF2α in leucocytes from control subjects after treatment with the ER 
stress activator tunacamycin, but not in BD patient–derived leucocytes, suggesting that 
dysfunction in the ER stress response and/or eIF2α signaling may also be associated with 
BD (Pfaffenseller and others 2014). 
microRNA 
The association of miRNAs with BD pathophysiology, risks, and treatments has been 
established by several studies, including analysis of miRNA expression in postmortem brain 
tissue (mostly PFC) and blood, as well as genetic studies. This has been nicely reviewed by 
Fries and colleagues in a recent publication (Fries and others 2018). 
RNA-BINDING PROTEINS 
Only a few lines of investigation have suggested a potential link between RBPs and BD. 
Fatemi et al. reported that BD individuals have reduced expression of FMRP in the lateral 
cerebellum, (Fatemi and others 2010). Another study showed that a nonsense mutation in 
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RBM12 was carried by 10 members of an Icelandic family suffering from psychosis, and two 
among them suffering from BD (Steinberg and others 2017). Moreover, the RNA-binding 
motif protein 3 (RBM3) levels were significantly higher in BD patient–derived neural 
progenitor cells that responded to the mood stabilizer lithium, compared with nonresponders, 
suggesting that increased levels of RBM3 might be required for positive response to lithium 
treatment (Papadima and others 2017). 
ADDICTION 
Addiction is a chronically relapsing disorder characterized by compulsive drug seeking and 
taking despite adverse consequences (Koob and Volkow 2016). Drug addiction affects 
approximately 10% of the population, and incurs significant societal costs, estimated to 
exceed $700 billion in the United States (Volkow and others 2016). 
mTORC1 
Drugs of abuse are believed to usurp the molecular mechanisms and signaling pathways of 
learning and memory processes, leading to maladaptive formation of drug-dependent 
memories (Torregrossa and others 2011). mTORC1 is a central player in protein synthesis-
dependent plasticity changes underlying learning and memory (Graber and others 2013), 
and growing evidence is now pointing toward mTORC1 also being a master regulator in 
synaptic neuroadaptations induced by drugs of abuse, leading to pathological drug taking 
and addiction (Neasta and others 2014; Ron and Barak 2016). The first evidence suggesting 
that mTORC1 plays a role in drug addiction came from a study by Narita and colleagues, 
which found that methamphetamine administration activates S6K in the nucleus accumbens 
(NAc) of rats and that rapamycin abolishes the development of methamphetamine 
sensitization (Narita and others 2005). Accordingly, another study reported that inhibition of 
mTORC1 in the hippocampus protects against amphetamine-induced seizures in rats 
(Renard and others 2016). However, Biever et al. showed that amphetamine administration 
increases the phosphorylation of S6 in the striatum but demonstrated that this increase was 
independent of mTORC1 and rather requires PKA activation (Biever and others 2015a). 
Interestingly, the authors showed that the increased S6 phosphorylation did not correlate 
with increased translation, contributing to the ongoing debate regarding the causal 
relationship between S6 phosphorylation and protein synthesis (Biever and others 2015a; 
Biever and others 2015b). Follow-up studies provided evidence for the association between 
mTORC1 signaling and cocaine addiction. Cocaine was shown to activate mTORC1 in 
reward-related brain regions and systemic administration of rapamycin was reported to 
suppress conditioned place preference (CPP) to cocaine in rodents (Bailey and others 2012; 
Wu and others 2011). In addition, the authors reported that cocaine administration leads to a 
transient increase in S6 phosphorylation in the NAc, dorsal striatum, PFC, and ventral 
tegmental area (VTA) of rats, which was abolished by rapamycin treatment (Bailey and 
others 2012; Wu and others 2011). In line with these results, mTOR deletion in the VTA of 
mice was shown to increase firing of GABAergic neurons, decrease dopamine release in the 
NAc, and attenuate cocaine-induced CPP (Liu and others 2018). Indeed, cocaine increases 
the extracellular levels of dopamine in the NAc, and we and others showed that activation of 
the dopamine D1 receptors (D1R) in the NAc of rodents activates mTORC1 signaling 
(Beckley and others 2016; Sutton and Caron 2015). The possibility that cocaine activates 
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mTORC1 in the NAc via D1R stimulation also stemmed from the finding that systemic 
administration of a D1R-antagonist blocked the cocaine-dependent activation of mTORC1 
(Sutton and Caron 2015). Sutton and Carron further showed that deletion of mTOR or Raptor 
specifically in D1R neurons reduced cocaine-induced hyperlocomotion (Sutton and Caron 
2015). Interestingly, another group reported that mTOR-dependent neural plasticity is also 
required for the process of drug relapse, by showing that mTORC1 inhibition in the NAc 
attenuated cue-induced reinstatement of cocaine seeking but had no effect on cocaine self-
administration (Wang and others 2010). Moreover, James et al. showed that withdrawal from 
cocaine self-administration increases mTORC1 activity in the NAc, and that rapamycin 
attenuates the progressive ratio breakpoint in a cocaine self-administration paradigm 
suggesting a role for mTORC1 in the motivation to seek cocaine (James and others 2014; 
James and others 2016). In line with previous findings, inhibition of mTORC1 in the NAc also 
reduced the expression of incubated cocaine craving (Werner and others 2018). Together, 
these results highlight a central role for mTORC1 in stimulants-dependent neuroadaptations. 
The involvement of mTORC1 in drug-induced neuroadaptations also extends to opiates. 
Specifically, acute systemic rapamycin administration suppressed cue-induced drug craving 
in abstinent heroin addicts (Shi and others 2009), and prevented drug seeking via disrupting 
reconsolidation of morphine memories in rats (Lin and others 2014). In addition, mTORC1 
activity was increased in the hippocampus of rats following morphine CPP, and intra-
hippocampal administration of rapamycin prevented the CPP acquisition (Cui and others 
2010). In addition, the kappa opioid receptor agonist U50,488H activates mTORC1 in the 
striatum and cortex of mice and rapamycin administration reduced kappa agonist–induced 
aversion (Liu and others 2019). Finally, Mazei-Robison and colleagues reported a long-
lasting activation of mTORC1 signaling in the VTA following repeated morphine 
administration (Mazei-Robison and others 2011). mTORC1 signaling has also been reported 
to be activated by cannabinoids. A single injection of tetrahydrocannabinol (THC) rapidly 
increased mTORC1 activity in the hippocampus, striatum, PFC, and amygdala of mice 
(Puighermanal and others 2009; Puighermanal and others 2013). Furthermore, systemic 
administration of rapamycin reduced schizophrenia-like phenotypes produced by chronic 
THC exposure in mice. (Ibarra-Lecue and others 2018). Interestingly, a single administration 
of another cannabis-derived phytochemical, cannabidiol (CBD), produced rapid 
antidepressant-like effects and increased the expression of synaptic proteins in the PFC of 
rodents, which were reversed by intra-cerebroventricular injection of rapamycin (Sales and 
others 2019). These studies suggest an involvement of mTORC1 signaling in the actions of 
both THC and CBD. 
Excessive alcohol drinking also activates mTORC1 in key brain regions of the cortico-striatal-
limbic system of rodents. Specifically, we reported that repeated cycles of binge drinking and 
withdrawal activate mTORC1 in the NAc shell and orbitofrontal cortex (OFC), as evidenced 
by increased phosphorylation levels of its downstream targets 4E-BP1, S6K, and S6 
(Laguesse and others 2017a; Neasta and others 2010). We further showed that 
administration of the specific mTORC1 inhibitors rapamycin and Rapalink-1 decreases 
rodent alcohol consumption and alcohol place preference (Beckley and others 2016; Morisot 
and others 2018; Neasta and others 2010). In addition, we reported that alcohol-dependent 
activation of mTORC1 in the NAc of mice initiates the translation of the synaptic proteins Arc, 
PSD-95, GLUA1, HOMER, the collapsing response mediator protein 2 (CRMP2), and 
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Prosap2-interacting protein 1 (Prosapip-1) (Beckley and others 2016; Laguesse and others 
2017b; Liu and others 2017; Neasta and others 2010). We further provided evidence to 
suggest that the alcohol-dependent mTORC1-mediated synaptic protein synthesis plays a 
crucial role in molecular and cellular-adaptations that in turn drive alcohol drinking behaviors 
(Laguesse and others 2017b; Liu and others 2017). Specifically, we showed that the 
consequence of alcohol-dependent mTORC1-mediated increases in CRMP2 and Prosapip1 
synthesis in the NAc were microtubules polymerization and F-actin assembly, respectively 
(Liu and others 2017; Laguesse and others 2017b). We further showed that the downstream 
consequences of Prosapip1-dependent F-actin assembly are spine maturation and the 
enhancement of activity of the GluA2-lacking AMPAR (Laguesse and others 2017b). 
Importantly, both CRMP2 and Prosapip1 in the NAc play a role in mechanisms that underlie 
heavy alcohol use (Laguesse and others 2017b; Liu and others 2017). In addition, we found 
that CRMP2 also contribute to mechanisms underlying alcohol-priming induced 
reinstatement of alcohol CPP (Ben Hamida and others 2018). Finally, we demonstrated that 
reconsolidation of alcohol-related memories activates mTORC1 signaling in the central 
amygdala (CeA) and several cortical regions, resulting in increased levels of synaptic 
proteins, and that systemic and intra-CeA administration of rapamycin disrupted alcohol-
associated memories and reduced relapse to alcohol seeking (Barak and others 2013). 
Together, these findings suggest a central role for mTORC1-dependent neuroadaptations 
that underlie alcohol reward, seeking, drinking and relapse. In summary, mTORC1 is a 
convergent point of most if not all drugs of abuse (Fig 7). 
TRANSLATION INITIATION AND ELONGATION FACTORS 
Translational control by eIF2α kinases is critical for long-lasting plasticity of synaptic 
connections underlying memory and cognitive functions (Trinh and Klann 2013). Growing 
evidence suggest that phospho-eIF2α-mediated control of translation could also participate in 
the formation of drug-induced maladaptive memories underlying addiction. 
Figure 7. Central role of mTORC1 in psychiatric disorders.  
 
Legend. Increasing evidence suggest a central role for mTORC1 in the development of major 
depressive disorder (MDD), bipolar disorder (BD), and addiction. Malfunction in mTORC1 signaling in 
the PFC and consequent impairment of synaptic plasticity contribute to the pathology of MDD. Clinical 
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studies and rodent models of BD have reported a dual involvement of mTORC1 signaling in BD 
pathophysiology, suggesting that mTORC1 signaling may be differentially dysregulated in striatal and 
cortical areas, but converging both toward the development of mania-like behaviors. Finally, mTORC1 
appears as a focal point of distinct signaling cascades that govern drug-induced synaptic plasticity and 
consequent neuroadaptations in different reward-related brain regions. ACC = anterior cingulate 
cortex; NAc = nucleus accumbens; OFC = orbito-frontal cortex; PFC = prefrontal cortex; VTA = ventral 
tegmental area. 
 
Specifically, Huang, Placzek, and colleagues showed that cocaine hijacks eIF2α-dependent 
translational control, and initiates synaptic potentiation in VTA neurons to induce addiction-
related behaviors (Huang and others 2016; Placzek and others 2016b). The authors also 
reported that adult mice with reduced phospho-eIF2α levels in the VTA exhibited higher 
cocaine-induced long-term potentiation (LTP) (Huang and others 2016; Placzek and others 
2016b). Furthermore, reduced eIF2α phosphorylation in the VTA was shown to increase 
cocaine CPP, whereas adolescent mice, exhibiting higher phospho-eIF2α levels, were more 
resilient to cocaine’s effects (Huang and others 2016; Placzek and others; 2016b). 
Interestingly, the same group found that reduced eIF2α phosphorylation may also enhance 
susceptibility to nicotine in humans and rodents, suggesting a common effect of both drugs 
on eIF2α signaling (Placzek and others 2016a). Moreover, re-exposure to a previous 
morphine- or cocaine-paired context increased eIF2α phosphorylation levels in the 
basolateral amygdala (BLA) of rats, whereas inhibition of eIF2α dephosphorylation disrupted 
the consolidation of morphine- and cocaine- induced CPP as well as heroin seeking behavior 
(Jian and others 2014). Together, these data suggest that eIF2α phosphorylation plays a 
major role in memory reconsolidation of drug-paired stimuli. Finally, Biever et al. reported 
that repeated amphetamine exposure enhances eIF2α phosphorylation in the striatum of 
mice, resulting in a global decrease in mRNA translation but also in a specific increase in Arc 
translation (Biever and others 2016), reinforcing the hypothesis that drug-induced 
dysregulation of eIF2α signaling activates the translation of specific synaptic mRNAs. 
Although cellular and molecular evidence point to a major role played by eEF2 in mRNA 
translation underlying learning and memory (Taha and others 2013), only a few studies have 
implicated elongation factors in addiction. For example, Meyers and colleagues identified an 
association between frequency of alcohol consumption in humans and genetic variants in the 
mGluR-eEF2-AMPA pathway (Meyers and others 2015). Importantly, the authors identified a 
hypermethylation of one CpG site in the 3′UTR of eEF2 in heavy alcohol users, suggesting 
an involvement of eEF2-dependent regulation of translation in AUD (Meyers and others, 
2015). 
microRNAS 
Over the past years, miRNAs have been heavily implicated in drug addiction (Smith and 
Kenny 2018). For instance, extended access to cocaine self-administration, increases the 
expression of miR-212 in the dorsomedial striatum, miR-101b, miR-137, miR-212 and miR-
232 in the NAc shell, and miR-137 in the dorsolateral striatum (DLS) (Hollander and others 
2010; Quinn and others 2018). Hollander and colleagues showed in a very elegant study that 
miR-212 negatively controls cocaine intake by suppressing the activity of Sprouty-related 
EVH1 domain-containing protein 1 (SPRED1), an endogenous inhibitor of rapidly accelerated 
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fibrosar-coma 1 (RAF1), amplifying the production of cAMP and the consequent activity of 
cAMP responsive element protein (CREB) (Hollander and others 2010). They thus identified 
a role for miR-212 in protection against development of compulsive cocaine taking (Hollander 
and others 2010). Furthermore, acute cocaine administration down-regulated miR-495 in the 
NAc, alleviating inhibition of its targets BDNF, CaMKIIa, and Arc, key players in synaptic 
plasticity underlying addiction (Bastle and others 2018). Conversely, overexpression of miR-
495 in the NAc attenuated the upregulation of synaptic translation and reduced motivation to 
self-administer and seek cocaine (Bastle and others 2018). miR-9 was shown to be up-
regulated in the mouse striatum following exposure to alcohol, mediating post-transcriptional 
reorganization of BK channels by targeting the 3′UTR of specific splice variants that are 
associated with increased sensitivity to alcohol (Pietrzykowski and others 2008). miR-124a, 
on the other hand, is down-regulated in the DLS following alcohol consumption and miR-
124a overexpression enhanced alcohol drinking and alcohol CPP (Bahi and Dreyer 2013). 
We found that miR-30a-5p, a miRNA targeting BDNF, is upregulated in the PFC of mice 
consuming excessive amounts of alcohol and demonstrated that miR-30a-5p plays a role in 
the transition from moderate to excessive alcohol intake (Darcq and others 2015). 
Specifically, overexpression of miR-30a-5p in the PFC reduced BDNF expression and 
produced an escalation of alcohol intake, whereas miR-30a-5p inhibition restored BDNF 
levels and decreased excessive alcohol intake (Darcq and others 2015). Withdrawal from 
chronic alcohol exposure was accompanied by the upregulation of miR-206 which also 
targets BDNF, promoting escalation of alcohol self-administration (Tapocik and others 2014). 
Furthermore, miR-411, miR-203, miR-92a, and miR-137 were reduced in the PFC of mice 
following chronic alcohol drinking, and silencing of miR-411 decreased the maintenance but 
not the development of alcohol consumption in mice (Most and others 2018). miRNAs are 
also involved in opioids actions. For instance, morphine was shown to up-regulate let-7 
expression, which led to the down-regulation of the mu opioid receptors and to the 
development of opioid tolerance (He and Wang 2012). Wang et al. showed that chronic 
morphine treatment decreased the expression of miR-219-5p in the spinal cord of rats, and 
that miR-219-5p overexpression prevented the development of morphine tolerance (Wang 
and others 2017). 
RNA-BINDING PROTEINS 
Over the past years, accumulating evidence suggested that RBPs may also influence 
neurobehavioral dysfunction underlying addiction (Bryant and Yazdani 2016). FMRP has 
been directly implicated in addiction to psychostimulants. Smith and colleagues reported that 
loss of FMRP impaired behavioral sensitization at moderate cocaine doses and enhanced 
the development of stereotypy at higher doses but had no effect on cocaine reward (Smith 
and others 2014). In addition, the authors showed that FMRP-deficient mice exhibited 
abnormalities in dendritic morphology and glutamatergic neurotransmission in the NAc 
following cocaine treatment (Smith and others 2014). Mutations in the FMRP-interacting 
protein CYFIP, which inhibits mRNA translation of synaptic proteins, have been shown to 
modulate sensitization induced by psychostimulants (Kumar and others 2013). Recent 
studies also linked FMRP to alcohol’s actions. Specifically, chronic alcohol exposure 
significantly increased FMRP phosphorylation in the hippocampus, and induced changes in 
NMDAR and Kv4.2 channel expression (Spencer and others 2016). Moreover, Wolfe and 
collaborators showed that alcohol promotes the synthesis of GABAB receptors (GABABR) 
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via FMRP (Wolfe and others 2016). Other RBPs have been less studied, but evidence 
showing their implication in drug of abuse-dependent dysregulation of local translation have 
started to emerge (Bryant and Yazdani 2016). For example, polypyrimidine tract binding 
protein 1 (PTBP1) and the RNA-binding protein, NOVA-1 bidirectionally regulate the short 
and long splice forms of the dopamine D2 receptor (Park and others 2011; Sasabe and 
others 2011). It has also been suggested that ELAV-like RBPs regulate the translation of 
synaptic plasticity-related mRNAs such as BDNF and induce behavioral adaptations in 
response to cocaine and other drugs of abuse (Bryant and Yazdani 2016; Tiruchinapalli and 
others 2008). For example, ELAV-4/HuD has been shown to regulate networks associated 
with addiction-like behaviors, including BDNF and CaMKII (Oliver and others 2018), and 
mice overexpressing HuD under the CaMKIIa promoter exhibited increased cocaine CPP 
compared with controls (Oliver and others 2018). Moreover, ectopic expression of ZBP1 in 
forebrain neurons impaired cocaine CPP (Lapidus and others 2012). Other RBPs have also 
been suggested to be involved in drug addiction and have been reviewed elsewhere (Bryant 
and Yazdani 2016). 
Concluding Remarks 
Aberrant synaptic plasticity is a common feature found in a number of psychiatric disorders, 
including addiction. As experience-dependent changes in synaptic strength are controlled in 
part by rapid local translation of mRNAs at synaptic sites, it is likely that impaired local 
translation is a central point for abnormal synaptic function and a common feature in the 
mechanisms underlying psychiatric disorders. For example, impairments in mTORC1 
function have been associated with a variety of psychiatric diseases such as MDD, SZ, and 
BD and addiction, even though each of these disorders has different characteristics and 
symptoms (Fig. 7). Interestingly, mTORC1 signaling is also linked to the mechanism of action 
of diverse classes of drugs of abuse, that is, psychostimulants, opiates, alcohol, and 
cannabis (Fig. 7). It is therefore intriguing that different drugs of abuse, by activating different 
receptors and downstream signaling pathways, converge on mTORC1 to induce maladaptive 
synaptic plasticity to promote addiction-related behaviors. Although the precise mechanisms 
underlying drug-dependent modulation of mTORC1 activity and the consequent 
modifications in synaptic plasticity are only beginning to be understood, all these findings 
point toward mTORC1 as being a key effector of drug of abuse-dependent neuroadaptations. 
As mTORC1 is a master regulator of local dendritic translation and synaptic plasticity, it is not 
surprising that impaired synaptic plasticity through mTORC1, underlies the development of 
numerous psychiatric disorders (Fig. 7). 
Apart from mTORC1, the initiation factor eIF2α and the elongation factor eEF2 also appear 
to be dysregulated in a variety of psychiatric disorders and adduction. eIF2α and eEF2 are 
also important players in the regulation of local translation and synaptic plasticity, and as 
such, their involvement in different psychiatric diseases is not surprising. 
Furthermore, miRNAs which are responsible for mRNA degradation and repression of 
translation also play a critical role in the persistent neuroadaptations associated with 
psychiatric disorders and drug. Finally, RBPs are numerous and their functions have only 
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started to be elucidated, but accumulating evidence suggests an important role for RBPs in 
local translation defects and in the development of psychiatric disorders. Although common 
mechanisms for RBPs are still to be demonstrated, it is very likely that in the following years, 
their importance in local translation control underlying the development of psychiatric 
diseases will emerge. Together, the evidence described herein support the idea that 
malfunction of local protein synthesis is a common theme in the mechanisms underlying the 
pathophysiology of psychiatric disorders. 
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